Flecainide for Treating Arrhythmias: Recommended Use and Dosage
Indications and Efficacy
- Flecainide is indicated primarily for supraventricular tachyarrhythmias including atrial fibrillation, AVNRT (AV nodal reentrant tachycardia), and AVRT (AV reentrant tachycardia) in patients without structural heart disease 1, 2, 3
- In randomized controlled trials, flecainide has shown a 93% probability of effective treatment (defined as <2 attacks of arrhythmia over 12 months) for supraventricular tachycardias 1
- Flecainide has demonstrated superior efficacy compared to verapamil for long-term management, with 30% of patients experiencing complete suppression of all symptomatic episodes on flecainide versus only 13% on verapamil 2, 4
Dosing Recommendations
- For "pill-in-the-pocket" approach (single-dose therapy for acute conversion of recent-onset atrial fibrillation): 200-300 mg as a single oral dose, after safety has been established in the hospital setting 5
Contraindications and Precautions
- Absolute contraindications: Structural heart disease, coronary artery disease, or reduced left ventricular ejection fraction 1, 2, 6
- Flecainide has been associated with increased mortality in patients with prior myocardial infarction and should be avoided in this population 6
Adverse Effects
- Discontinuation rates due to adverse effects range from 5-20% in clinical trials 2
Special Considerations
- When used for paroxysmal atrial fibrillation, the "pill-in-the-pocket" approach requires careful patient selection and initial in-hospital evaluation 5, 6
- Flecainide is often combined with beta-blocking agents to enhance efficacy and reduce the risk of one-to-one conduction over the AV node if atrial flutter occurs 2, 4